Cargando…

Introducing the non-invasive prenatal testing for detection of Down syndrome in China: a cost-effectiveness analysis

OBJECTIVE: This study aimed to compare the health economic value of a non-invasive prenatal testing (NIPT) strategy against a second-trimester triple screening (STS) strategy for the detection of Down syndrome based on real-world data from China. DESIGN: A decision-analytical model was developed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Wenru, Wan, Yang, Chen, Jianan, Du, Yanqiu, Huang, Jiayan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261875/
https://www.ncbi.nlm.nih.gov/pubmed/34230019
http://dx.doi.org/10.1136/bmjopen-2020-046582
_version_ 1783719085217939456
author Shang, Wenru
Wan, Yang
Chen, Jianan
Du, Yanqiu
Huang, Jiayan
author_facet Shang, Wenru
Wan, Yang
Chen, Jianan
Du, Yanqiu
Huang, Jiayan
author_sort Shang, Wenru
collection PubMed
description OBJECTIVE: This study aimed to compare the health economic value of a non-invasive prenatal testing (NIPT) strategy against a second-trimester triple screening (STS) strategy for the detection of Down syndrome based on real-world data from China. DESIGN: A decision-analytical model was developed to compare the cost-effectiveness of five strategies from a societal perspective. Cost and probability input data were obtained from the real-world surveys and published sources. SETTING: China. PARTICIPANTS: Women with a singleton pregnancy. INTERVENTIONS: The five strategies for screening were: (A) maternal age with STS (no NIPT); (B) STS plus NIPT screening; (C) age-STS plus NIPT screening (the currently referral strategy in China); (D) maternal age with NIPT screening and (E) universal NIPT screening. MAIN OUTCOME MEASURES: Incremental cost-effectiveness ratios (ICERs) per additional Down syndrome case terminated, univariate and probabilistic sensitivity analysis and cost-effectiveness acceptability curves were obtained. RESULTS: Strategy A detected the least number of Down syndrome cases. Compared with the cheapest Strategy B, Strategy D had the lowest ICER (incremental cost, US$98 944.85 per additional Down syndrome case detected). Strategy D had the highest probability of being cost-effective at the willingness-to-pay level between US$110 000.00 and US$535 000.00 per additional Down syndrome case averted. Strategy E would not be cost-effective unless the unit cost of the NIPT could be decreased to US$60.50. CONCLUSION: Introducing NIPT screening strategies was beneficial over the use of STS strategy alone. Evaluating maternal age in combination with the NIPT screening strategy performs better than China’s currently referral strategy in terms of cost-effectiveness and safety. Lowering the price of NIPT and optimising payment methods are effective measures to promote universal NIPT strategies in China.
format Online
Article
Text
id pubmed-8261875
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-82618752021-07-23 Introducing the non-invasive prenatal testing for detection of Down syndrome in China: a cost-effectiveness analysis Shang, Wenru Wan, Yang Chen, Jianan Du, Yanqiu Huang, Jiayan BMJ Open Health Economics OBJECTIVE: This study aimed to compare the health economic value of a non-invasive prenatal testing (NIPT) strategy against a second-trimester triple screening (STS) strategy for the detection of Down syndrome based on real-world data from China. DESIGN: A decision-analytical model was developed to compare the cost-effectiveness of five strategies from a societal perspective. Cost and probability input data were obtained from the real-world surveys and published sources. SETTING: China. PARTICIPANTS: Women with a singleton pregnancy. INTERVENTIONS: The five strategies for screening were: (A) maternal age with STS (no NIPT); (B) STS plus NIPT screening; (C) age-STS plus NIPT screening (the currently referral strategy in China); (D) maternal age with NIPT screening and (E) universal NIPT screening. MAIN OUTCOME MEASURES: Incremental cost-effectiveness ratios (ICERs) per additional Down syndrome case terminated, univariate and probabilistic sensitivity analysis and cost-effectiveness acceptability curves were obtained. RESULTS: Strategy A detected the least number of Down syndrome cases. Compared with the cheapest Strategy B, Strategy D had the lowest ICER (incremental cost, US$98 944.85 per additional Down syndrome case detected). Strategy D had the highest probability of being cost-effective at the willingness-to-pay level between US$110 000.00 and US$535 000.00 per additional Down syndrome case averted. Strategy E would not be cost-effective unless the unit cost of the NIPT could be decreased to US$60.50. CONCLUSION: Introducing NIPT screening strategies was beneficial over the use of STS strategy alone. Evaluating maternal age in combination with the NIPT screening strategy performs better than China’s currently referral strategy in terms of cost-effectiveness and safety. Lowering the price of NIPT and optimising payment methods are effective measures to promote universal NIPT strategies in China. BMJ Publishing Group 2021-07-06 /pmc/articles/PMC8261875/ /pubmed/34230019 http://dx.doi.org/10.1136/bmjopen-2020-046582 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Health Economics
Shang, Wenru
Wan, Yang
Chen, Jianan
Du, Yanqiu
Huang, Jiayan
Introducing the non-invasive prenatal testing for detection of Down syndrome in China: a cost-effectiveness analysis
title Introducing the non-invasive prenatal testing for detection of Down syndrome in China: a cost-effectiveness analysis
title_full Introducing the non-invasive prenatal testing for detection of Down syndrome in China: a cost-effectiveness analysis
title_fullStr Introducing the non-invasive prenatal testing for detection of Down syndrome in China: a cost-effectiveness analysis
title_full_unstemmed Introducing the non-invasive prenatal testing for detection of Down syndrome in China: a cost-effectiveness analysis
title_short Introducing the non-invasive prenatal testing for detection of Down syndrome in China: a cost-effectiveness analysis
title_sort introducing the non-invasive prenatal testing for detection of down syndrome in china: a cost-effectiveness analysis
topic Health Economics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261875/
https://www.ncbi.nlm.nih.gov/pubmed/34230019
http://dx.doi.org/10.1136/bmjopen-2020-046582
work_keys_str_mv AT shangwenru introducingthenoninvasiveprenataltestingfordetectionofdownsyndromeinchinaacosteffectivenessanalysis
AT wanyang introducingthenoninvasiveprenataltestingfordetectionofdownsyndromeinchinaacosteffectivenessanalysis
AT chenjianan introducingthenoninvasiveprenataltestingfordetectionofdownsyndromeinchinaacosteffectivenessanalysis
AT duyanqiu introducingthenoninvasiveprenataltestingfordetectionofdownsyndromeinchinaacosteffectivenessanalysis
AT huangjiayan introducingthenoninvasiveprenataltestingfordetectionofdownsyndromeinchinaacosteffectivenessanalysis